Summary Eighty-one patients with small cell lung cancer (SCLC) with a survival of more than 2 years after start of chemotherapy were studied. Twenty-six of the 28 patients who died of relapsed SCLC had in fact relapsed before two years and of the 55 who had not then only two (4%) relapsed subsequently. It is stressed that with such observations treatment related factors should be taken in account. Second tumours were observed in ten patients, nine proven malignant. Of the eight patients with non-small cell lung cancer three had residual disease after initial chemotherapy. In our patient group after a 2 year disease-free interval the risk of developing non-small cell lung cancer seems higher than a subsequent relapse of SCLC.
Summary Eighty-one patients with small cell lung cancer (SCLC) with a survival of more than 2 years after start of chemotherapy were studied. Twenty-six of the 28 patients who died of relapsed SCLC had in fact relapsed before two years and of the 55 who had not then only two (4%) relapsed subsequently. It is stressed that with such observations treatment related factors should be taken in account. Second tumours were observed in ten patients, nine proven malignant. Of the eight patients with non-small cell lung cancer three had residual disease after initial chemotherapy. In our patient group after a 2 year disease-free interval the risk of developing non-small cell lung cancer seems higher than a subsequent relapse of SCLC.
In recent years a number of studies have been published concerning prognostic factors of patients with small-cell lung cancer (SCLC) . Most patients who achieve long-term survival after treatment for SCLC initially present with favourable prognostic factors such as good performance status, limited disease, female gender, few biochemical abnormalities and good response to treatment (Albain et al., 1990; Osterlind & Anderson, 1986; Spiegelman et al., 1989) . However when these patients have reached a survival of more than 2 or 3 years after start of treatment such factors have lost their predictive value for further disease-free survival or subsequent relapse.
A number of studies have focused solely on those patients who achieve long-term survival (Davis et al., 1985; Niiranen, 1988; Jackson et al., 1988; Pallares et al., 1987; Souhami & Law, 1990) . In order to gather more knowledge about the fate of patients with SCLC who obtain long-term survival we performed a retrospective study of all consecutively treated patients in four different centres with a survival of more than 24 months after start of treatment. Special attention was paid to subsequent relapse and the development of secondary malignancies. No attempt was made to study the differences in pretreatment prognostic factors between this group of patients and the parent group since these factors are well known from the literature.
Patients and methods
The medical records of all patients with SCLC defined according to the morphological criteria of the WHO (1982) Table I .
Results
The overall survival curve of the patients from 2 years after start of chemotherapy is shown in Figure 1 . At the time of analysis 43 patients had died with a median survival of 143 weeks (range . The causes of death are listed in Figure 2 shows the death from SCLC censored for non-SCLC deaths.
Twenty-six of these 28 patients had already evidence of disease progression before they had reached a survival 2 years after start of treatment. More than 60% of the twenty-three patients treated with reinduction chemotherapy achieved an objective response to second-line treatment. The two patients who had no evidence of disease 24 months after Non-malignant causes of death were found in three patients. In two patients the cause of death was unknown. Of the nine patients who received chemotherapy after surgical resection of the tumour, five patients are still alive without recurrent disease and a median survival of 70 months (range 52-120).
Of the 13 patients with extensive disease all patients had metastases to only one organ site. Four of these patients have still no evidence of disease with a follow-up of 65, 69, 72 and 80 months after start of chemotherapy. There was not a significant difference between the survival curves of the patients who were initially staged as limited or extensive disease beyond a survival of more than 2 years.
Discussion
Although SCLC is a chemosensitive disease the number of patients surviving for more than 2 years is still low and relapses as late as 8 years after diagnosis have been reported (Vogelsang et al., 1985) . As can be seen in Table I most of the patients who achieved long-term survival presented with initial favourable prognostic factors and most patients had few biochemical abnormalities.
Of the 81 patients with a survival of more than 24 months after start of treatment 35% died from progressive SCLC up till 55 months. The overall survival curve is quite similar to those reported by Souhami & Law (1990) . Remarkably only two of the 55 patients (4%) with a disease-free survival of more than 2 years have relapsed after a median follow-up of 5.7 years. reported on 72 patients disease-free at restaging 18 months after start of treatment. During the first 6 months after restaging 19 patients relapsed and 14 of 53 patients (26%) relapsed after a disease-free interval of more than 24 months with a minimum follow-up of 4 years. One explanation for this observed difference in relapse rates may be that in contrast to the Danish study 75% of our patients did not receive chemotherapy for a duration of more than 6 months. Although maintenance treatment has probably no impact on overall survival it seems to increase the disease-free interval (Spiro et al., 1989; Splinter, 1988) . Therefore patients who have received chemotherapy for 18 months and who are still disease-free at two years have a higher relapse rate than patients who have received chemotherapy for a shorter period. The favourable survival of some of the patients who had already relapsed before they had reached a survival for more than 2 years and the high response to reinduction chemotherapy also argues for this hypothesis (Postmus et al., 1987) .
Lung tumours with a non-small cell histology were encountered in eight patients. In three patients the non-small cell histology became apparent in the residual tumour after they had been given treatment for SCLC. Five patients were diagnosed with non-small cell carcinoma of the lung 19-84 months after the diagnosis of SCLC. Johnson et al. (1986) estimated the risk of development of non-small cell lung carcinoma after two years of disease-free survival 4.4% per person year. Since in our study 55 patients were disease-free at 24 months with a median follow-up of 5.7 years the expected number of patients who had developed non-small cell lung cancer would have been 8 patients. Despite the fact that all of these patients had been followed on a regular basis and therefore theoretically these tumours should have been detected at a rather early stage and furthermore at least five patients had operable disease at presentation, all these patients died due to distant metastases. Data about the prognosis of patients who develop a second primary lung carcinoma after small cell carcinoma are scarce. Craig et al. (1984) reported on ten patients of whom the survival after diagnosis of the second primary was greater than 6 months in only one patient. In the earlier mentioned study of Johnson no patient survived more than 40 weeks from histologic documentation of the second cancer (Johnson et al., 1986) . Until now there is no obvious explanation for the dismal prognosis of these patients.
In conclusion we observed in this study a low relapse rate (4%) of SCLC after a disease-free interval of more than 2 years. It is stressed that with such observations treatment related factors should be taken in account. Since after a 2 year disease-free interval the risk of developing NSCLC seems higher than a subsequent relapse of SCLC follow-up should be focused on early detection of a second primary. More data are required to show whether the prognosis of those patients who develop a second primary NSCLC is worse than those patients who develop a second primary NSCLC than of patients who develop NSCLC without antecedent SCLC and whether or not chemo-prevention trials in such a high risk group may be worthwhile.
